LGL Group (LGL) to Release Earnings on Thursday

LGL Group (NYSEAMERICAN:LGL) is expected to be posting its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to post earnings of $0.01 per share and revenue of $0.80 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 17, 2026 at 4:00 PM ET.

LGL Group Stock Performance

LGL stock opened at $7.25 on Wednesday. LGL Group has a fifty-two week low of $5.45 and a fifty-two week high of $7.57. The company has a market capitalization of $47.41 million, a price-to-earnings ratio of 725.73 and a beta of 0.32. The business’s 50 day moving average price is $6.94 and its two-hundred day moving average price is $7.05.

Institutional Investors Weigh In On LGL Group

An institutional investor recently raised its stake in LGL Group stock. Osaic Holdings Inc. raised its holdings in shares of LGL Group, Inc. (The) (NYSEAMERICAN:LGL) by 15.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 20,250 shares of the industrial products company’s stock after purchasing an additional 2,710 shares during the period. Osaic Holdings Inc. owned 0.38% of LGL Group worth $154,000 as of its most recent SEC filing. 30.28% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded LGL Group to a “hold” rating in a research report on Thursday, May 7th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Hold”.

LGL Group Company Profile

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.